About this trial
The aim of the study is to validate a global and simple score : IGA (Investigator Global Assessment) score for the evaluation of the extent and severity of the disease in patients with bullous pemphigoid
Eligibility criteria
Qualifiers
Consecutive adult patients aged ≥ 18 years
Newly diagnosed or relapsing BP
Clinical features suggestive of classic BP AND suggestive histological features AND deposition of IgG and/ or C3 deposits on the dermal epiderma junction, AND detection of circulating anti-epidermal antibodies labelling the epidermal side of salt-split skin
Patient having read and understood the information letter and not opposed to participation
Disqualifiers
Predominant or exclusive mucosal involvement leading to suspect the diagnosis of mucous membrane pemphigoid
Pemphigoid gestationis
Linear IgA dermatosis (predominant or exclusive IgA deposits on the DEJ)
Skin lesions suggesting the diagnosis of epidermolysis bullosa acquisita (skin fragility, atrophy, milia)
Trial design
Treatments tested in this trial
- IGA score
- BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)